77.50 0.00 (0.00%)
After hours: 4:10PM EDT
|Bid||77.45 x 1000|
|Ask||77.51 x 800|
|Day's range||77.31 - 78.80|
|52-week range||67.10 - 131.95|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||114.64|
|Earnings date||21 Oct 2020 - 26 Oct 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||110.48|
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between February 28, 2020 and August 18, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/bmrn.